Top Markets
#1 Glidr Glidr +51.75%
#2 Akedo Akedo +49.85%
#3 DOVU DOVU +47.86%
#4 Velvet Velvet +43.76%
#5 Black Phoenix Black Phoenix +34.36%
#6 Cross Cross +21.02%
#7 Perle Perle +19.03%
#8 τemplar τemplar +16.86%
#9 Cysic Cysic +15.93%
#10 Not in Employment, Education, or Training Not in Employment, Education, or Training +15.88%
Coin of the day
Glidr Glidr
Paramètres
Langue
FRANçAIS
Devise
USD
Thème
Chimeric Therapeutics Limited Chimeric Therapeutics Limited

Chimeric Therapeutics Limited

CHM
Classement en actions #38382
Chimeric Therapeutics Ltd. is an Australian clinical-stage biopharmaceutical... Chimeric Therapeutics Ltd. is an Australian clinical-stage biopharmaceutical firm dedicated to developing and commercializing a diverse array of cell therapies designed to combat various cancers. Its lead natural killer (NK) cell platform, CHM 0201, is currently undergoing Phase I clinical evaluation for both solid tumors and hematological malignancies. Another key candidate, CHM 1101 (a CLTX CAR T therapy), is also in Phase I trials, specifically targeting recurrent or progressive glioblastoma in patients expressing MMP2+. Beyond these, the company's development pipeline encompasses CHM 0301 for blood cancers; CLTX CAR NK (CHM 1301) and CDH17 CAR NK (CHM 2301) for solid tumors. The CLTX CAR T platform (CHM 1101) is additionally being investigated for melanoma, colorectal, and prostate cancers, while CDH17 CAR T (CHM 2101) is being developed for neuroendocrine, colorectal, pancreatic, and gastric cancers. Chimeric Therapeutics, headquartered in Carlton, Australia, was founded in 2020.
Prix de l'action
$0.02468497
Capitalisation boursière
$1.01M
Changement (1 jour)
-12.50%
Changement (1 an)
-87.34%
Pays
AU
Échange Chimeric Therapeutics Limited (CHM)

Catégorie

Healthcare
Bénéfices pour Chimeric Therapeutics Limited (CHM)
Bénéfices en 2026 TTM : 0
Selon les derniers rapports financiers de Chimeric Therapeutics Limited, les bénéfices actuels de l'entreprise sont de 0. En 2026, l'entreprise a réalisé un bénéfice de 0, égal à celui de 2026 qui était de 0. Les bénéfices affichés sur cette page correspondent aux bénéfices avant intérêts et impôts, appelés aussi EBIT.
Historique des bénéfices pour Chimeric Therapeutics Limited de 2026 à 2026
Bénéfices à la fin de chaque année
Année Bénéfices Changez
Pas assez de données pour les dates fournies.
Bénéfices des entreprises similaires ou concurrentes
Entreprise Bénéfices Différence de bénéfices Pays
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
$5.27B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
$1.95B -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
- -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
- -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
$3.01B -
BE